Detalhe da pesquisa
1.
Regulatory Role for NK Cells in a Mouse Model of Systemic Juvenile Idiopathic Arthritis.
J Immunol
; 203(12): 3339-3348, 2019 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31676671
2.
Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients.
J Gastroenterol Hepatol
; 34(7): 1175-1181, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-30589948
3.
Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn's Disease.
Clin Gastroenterol Hepatol
; 21(3): 838-840.e2, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34942369
4.
Evaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn's disease.
Therap Adv Gastroenterol
; 16: 17562848231189110, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37655059
5.
Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model.
iScience
; 25(8): 104705, 2022 Aug 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35813873
6.
Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab Concentrations.
J Crohns Colitis
; 15(6): 988-993, 2021 Jun 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33245363
7.
Development and validation of immunoassays for monitoring of guselkumab and anti-guselkumab antibodies in patients with moderate-to-severe psoriasis.
J Pharm Biomed Anal
; 189: 113433, 2020 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32615342
8.
Evaluating an easy sampling method using dried blood spots to determine vedolizumab concentrations.
J Pharm Biomed Anal
; 185: 113224, 2020 Jun 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32151929
9.
Achieving Mucosal Healing in Inflammatory Bowel Diseases: Which Drug Concentrations Need to Be Targeted?
Clin Pharmacol Ther
; 106(5): 945-954, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31420861
10.
Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates.
J Crohns Colitis
; 13(7): 864-872, 2019 Jul 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-30715258
11.
Defining a Minimal Effective Serum Trough Concentration of Secukinumab in Psoriasis: A Step toward Personalized Therapy.
J Invest Dermatol
; 139(10): 2232-2235.e1, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31067484